996 F.3d 1302
Fed. Cir.2021Background
- 10X Genomics sued Bio‑Rad at the ITC under 19 U.S.C. § 1337, alleging Bio‑Rad’s ddSEQ microfluidic systems infringe asserted claims of U.S. Pat. Nos. 9,689,024; 9,695,468; and 9,856,530. The ALJ found infringement and a qualifying domestic industry; the Commission affirmed. 10X appealed to the Federal Circuit.
- The asserted claims cover methods using gel beads (GEM architecture) bearing large numbers of releasably‑attached oligonucleotide barcode molecules that are released by a stimulus into droplets with nucleic‑acid analytes and then amplified/sequenced.
- Bio‑Rad’s accused ddSEQ uses porous gel beads with oligonucleotides released by an enzyme complex; Bio‑Rad contended key claim limitations are not met (stimulus applied to oligos not bead; solutions do not mix at first junction; barcoding occurs too early).
- 10X’s domestic products (GemCode/Chromium) were found to practice the asserted claims for purposes of the domestic‑industry requirement. The Commission rejected Bio‑Rad’s indefiniteness attack on the ’530 claims (forfeited and meritless).
- Bio‑Rad defended on ownership grounds, arguing two 10X inventors signed employment assignment agreements at QuantaLife/Bio‑Rad that conveyed rights to inventions conceived during employment; the ALJ and Commission found no co‑ownership because (a) the agreements cover only IP conceived during employment and (b) Bio‑Rad failed to prove conception of the inventive concept occurred before the inventors left.
Issues
| Issue | Plaintiff (10X) Argument | Defendant (Bio‑Rad) Argument | Held |
|---|---|---|---|
| Infringement of ’024 (stimulus requirement) | ddSEQ applies a stimulus to the gel bead to release oligonucleotides; oligos are part of the bead so claim met | Enzyme acts on oligonucleotides, not the gel material, so “applying a stimulus to said porous gel bead” is not satisfied | Commission/FC: substantial evidence supports finding enzyme acts on bead (oligos are part of bead) — infringement sustained |
| Infringement of ’468 (mixing at first junction) | Solutions meet and form an aqueous mixture at the first junction before droplet formation | Solutions remain separate until droplet formation (no aqueous mixture at first junction) | Commission/FC: credited 10X expert that solutions come together and are immediately formed into droplets — substantial‑evidence support for infringement |
| ’530 claim scope, infringement, and domestic‑industry ("≥1,000 droplets" timing) | Claim permits some detachment before 1,000 droplets so long as required barcoding occurs in each of the ≥1,000 droplets once they are generated; 10X products and ddSEQ meet that timing | Barcoding begins immediately upon droplet formation so requirement not met (barcoding completes before 1,000 droplets are formed) | Commission/FC: claim construction allows barcoding to begin early; substantial evidence supports finding bulk cleavage/barcoding occurs after ≥1,000 droplets and 10X products meet domestic‑industry requirement; indefiniteness forfeited and rejected on merits |
| Ownership/assignment via employment agreements (co‑inventorship) | Ideas and contributions developed at QuantaLife/Bio‑Rad made Hindson and Saxonov joint inventors; assignment language captures rights and thus Bio‑Rad co‑owns patents | Assignment clauses cover IP conceived/developed during employment only; inventive concept was conceived after employment and Bio‑Rad did not prove joint inventorship | Commission/FC: assignments are temporally limited to IP conceived during employment; substantial evidence shows inventive concept (gel‑bead GEM) conceived after employment and Bio‑Rad failed to prove joint inventorship — ownership defense rejected |
Key Cases Cited
- Guangdong Alison Hi‑Tech Co. v. Int’l Trade Comm’n, 936 F.3d 1353 (Fed. Cir. 2019) (standard of review for ITC decisions under the APA)
- Henny Penny Corp. v. Frymaster LLC, 938 F.3d 1324 (Fed. Cir. 2019) (substantial‑evidence standard explained)
- ATEN Int’l Co. v. Uniclass Tech. Co., 932 F.3d 1364 (Fed. Cir. 2019) (substantial‑evidence review of infringement findings)
- Alloc, Inc. v. Int’l Trade Comm’n, 342 F.3d 1361 (Fed. Cir. 2003) (domestic‑industry technical‑prong test compares domestic products to asserted claims)
- Israel Bio‑Eng’g Project v. Amgen, Inc., 475 F.3d 1256 (Fed. Cir. 2007) (contracts construed to limit assignment to inventions conceived during the agreement term)
- FilmTec Corp. v. Hydranautics, 982 F.2d 1546 (Fed. Cir. 1992) (conception during agreement supports assignment where contract language so provides)
- Bd. of Trustees of the Leland Stanford Junior Univ. v. Roche Molecular Sys., Inc., 583 F.3d 832 (Fed. Cir. 2009) (distinct contract language can produce different assignment outcomes)
- Whitewater West Indus., Ltd. v. Alleshouse, 981 F.3d 1045 (Fed. Cir. 2020) (policy concerns about post‑employment assignment clauses)
- Nevro Corp. v. Boston Sci. Corp., 955 F.3d 35 (Fed. Cir. 2020) (indefiniteness reviewed de novo where underlying facts undisputed)
- Semitool, Inc. v. Dynamic Micro Sys. Semiconductor Equip. GmbH, 444 F.3d 1337 (Fed. Cir. 2006) (contract interpretation under state law reviewed de novo)
- O2 Micro Int’l Ltd. v. Beyond Innovation Tech. Co., 521 F.3d 1351 (Fed. Cir. 2008) (claim construction amplification to resolve disputes does not imply indefiniteness)
- Pfizer, Inc. v. Teva Pharms. USA, Inc., 429 F.3d 1364 (Fed. Cir. 2005) (claim construction refinement is permissible during litigation)